Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion to extended-release MeltDose tacrolimus after kidney transplantation
2019-004946-13Phase 4Completed
- Sponsor
- University Hospital Tübingen
- Start
- May 2020
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus in kidney transplant (2 arms), sponsored by University Hospital Tübingen. Primary endpoints: Change in glucose metabolism and Change in blood lipid levels. Started May 2020; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney transplant
Beyond the preview
Go deeper on 2019-004946-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004946-13.